Novo Nordisk A/S $NVO Shares Sold by Manning & Napier Advisors LLC

Manning & Napier Advisors LLC cut its stake in shares of Novo Nordisk A/S (NYSE:NVO) by 8.4% in the fourth quarter, HoldingsChannel.com reports. The fund owned 166,932 shares of the company’s stock after selling 15,269 shares during the period. Manning & Napier Advisors LLC’s holdings in Novo Nordisk A/S were worth $8,550,000 at the end of the most recent reporting period.

A number of other large investors also recently added to or reduced their stakes in the stock. Smith Chas P & Associates PA Cpas raised its position in shares of Novo Nordisk A/S by 105.3% in the third quarter. Smith Chas P & Associates PA Cpas now owns 405,425 shares of the company’s stock valued at $22,497,000 after buying an additional 207,959 shares during the last quarter. Clifford Swan Investment Counsel LLC raised its position in shares of Novo Nordisk A/S by 13.7% in the third quarter. Clifford Swan Investment Counsel LLC now owns 311,168 shares of the company’s stock valued at $17,267,000 after buying an additional 37,453 shares during the last quarter. Markel Group Inc. raised its position in shares of Novo Nordisk A/S by 4.9% in the third quarter. Markel Group Inc. now owns 2,368,649 shares of the company’s stock valued at $131,436,000 after buying an additional 110,061 shares during the last quarter. WCM Investment Management LLC raised its position in shares of Novo Nordisk A/S by 3.7% in the third quarter. WCM Investment Management LLC now owns 2,732,182 shares of the company’s stock valued at $151,636,000 after buying an additional 97,477 shares during the last quarter. Finally, Quantbot Technologies LP acquired a new stake in shares of Novo Nordisk A/S in the third quarter valued at about $3,171,000. 11.54% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities research analysts have recently commented on the stock. Citigroup assumed coverage on shares of Novo Nordisk A/S in a research report on Tuesday, January 27th. They issued a “neutral” rating for the company. Wolfe Research assumed coverage on Novo Nordisk A/S in a report on Thursday, March 26th. They issued a “peer perform” rating for the company. Jefferies Financial Group raised Novo Nordisk A/S from an “underperform” rating to a “hold” rating in a report on Thursday, February 12th. CICC Research assumed coverage on Novo Nordisk A/S in a report on Friday, January 9th. They issued an “outperform” rating and a $73.50 price target for the company. Finally, Deutsche Bank Aktiengesellschaft cut Novo Nordisk A/S from a “buy” rating to a “hold” rating in a report on Monday, February 23rd. Four equities research analysts have rated the stock with a Buy rating, eighteen have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $65.56.

Novo Nordisk A/S News Summary

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Wegovy pill demand is surging, with reports of a “record-breaking” U.S. launch and more than 2 million prescriptions since January, strengthening confidence in Novo Nordisk’s growth outlook. Novo’s CEO champions “record-breaking start” for Wegovy pill in US market
• Positive Sentiment: Novo Nordisk raised its 2026 guidance after strong oral Wegovy prescriptions, suggesting the new formulation could offset some pricing pressure and support profits. Novo Nordisk Guidance Lift Tests Valuation As Oral Wegovy Demand Surges
• Positive Sentiment: Amazon is expanding access to Novo Nordisk’s Ozempic pill through same-day delivery and kiosks, which could broaden patient reach and improve adoption. Amazon Pharmacy Expands Access to New Ozempic® Pill via Same-Day Delivery, Kiosks
• Positive Sentiment: Analysts are lifting earnings estimates, reflecting confidence that the company’s recent momentum can carry into the next fiscal year. Hims & Hers Earnings Preview: The Novo Nordisk Shift Puts GLP-1 Strategy in Focus (NVO)
• Neutral Sentiment: Novo’s India sales jumped after price cuts boosted demand, but the growth also highlights intensifying competition from cheaper GLP-1 alternatives in key international markets. Novo Nordisk’s Ozempic India Price Cut Boosts Obesity Drug Sales
• Neutral Sentiment: Broader investor focus remains on whether the Wegovy pill can expand the GLP-1 market enough to offset pricing pressure and competition from Eli Lilly. Novo and Lilly gain on signs weight-loss pills could expand the market
• Negative Sentiment: Generic Ozempic competition is beginning to emerge in Canada, raising concern that semaglutide revenue could weaken internationally over time. Healthy Returns: First Ozempic generics in Canada will be a test case for Novo Nordisk

Novo Nordisk A/S Price Performance

Novo Nordisk A/S stock opened at $46.02 on Friday. Novo Nordisk A/S has a 12-month low of $35.12 and a 12-month high of $81.44. The stock has a market cap of $205.47 billion, a P/E ratio of 10.80, a PEG ratio of 10.74 and a beta of 0.77. The company has a 50-day moving average price of $38.71 and a 200 day moving average price of $46.97. The company has a current ratio of 0.79, a quick ratio of 0.57 and a debt-to-equity ratio of 0.59.

Novo Nordisk A/S (NYSE:NVO) last released its quarterly earnings data on Tuesday, March 31st. The company reported $1.03 earnings per share (EPS) for the quarter. Novo Nordisk A/S had a net margin of 37.23% and a return on equity of 63.31%. The firm had revenue of $10.85 billion during the quarter. Sell-side analysts anticipate that Novo Nordisk A/S will post 3.39 earnings per share for the current year.

About Novo Nordisk A/S

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.